Brian Boes, MD
Neurology · Lincoln, NENPI 1295784643
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 68.1% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2020 at $5,236 and has fallen 96.1% since, to $205 in 2025.
Across 134 payments — averaging $56.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Teva Pharmaceuticals USA, Inc.$471
- Eisai Inc.$156
- Neurelis, Inc.$149
- UCB, Inc.$143
- Biogen$123
- plus $1K from 35 others
What the payments were for
- Speaking & faculty fees$3,91352%
- Travel & lodging$72210%
- Food & beverage$2,50733%
- Education$4176%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $5,151 |
| Teva Pharmaceuticals USA, Inc. | 13 | $471 |
| Eisai Inc. | 3 | $156 |
| Neurelis, Inc. | 10 | $149 |
| UCB, Inc. | 8 | $143 |
| Biogen | 6 | $123 |
| Lundbeck LLC | 6 | $116 |
| Lilly USA, LLC | 4 | $108 |
| Sanofi | 4 | $84 |
| Johnson & Johnson | 4 | $71 |
| Novartis | 4 | $61 |
| Genentech USA, Inc. | 3 | $55 |
| Arbor Pharmaceuticals, Inc. | 3 | $55 |
| Avanir Pharmaceuticals, Inc. | 4 | $51 |
| Amgen | 3 | $51 |
| Tanabe Pharma America, Inc. | 3 | $50 |
| GE HealthCare | 3 | $46 |
| SK Life Science, Inc. | 2 | $40 |
| MDD US Operations, LLC | 2 | $38 |
| Novo Nordisk | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Medtronic(2 entities) | 2 | $32 |
| CSL Behring | 1 | $32 |
| Acadia Pharmaceuticals Inc | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Neurocrine Biosciences, Inc. | 2 | $31 |
| Bristol Myers Squibb | 2 | $30 |
| AstraZeneca | 2 | $29 |
| Greenwich Biosciences, Inc. | 1 | $29 |
| Zogenix Inc. | 1 | $28 |
| Pfizer | 1 | $25 |
| EMD Serono, Inc. | 2 | $23 |
| Chiesi USA, Inc. | 1 | $22 |
| GRT US Holding, Inc. | 1 | $22 |
| Adamas Pharmaceuticals, Inc. | 1 | $19 |
| Genentech, Inc. | 1 | $17 |
| Merz Pharmaceuticals, LLC | 1 | $16 |
| NS Pharma, Inc. | 1 | $16 |
| Acorda Therapeutics, Inc | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,559 in reported general payments places this provider in the 75th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $93,653 |
| Nurtec OdtRimegepant Sulfate | 27 | $38,466 |
| Emgality PenGalcanezumab-Gnlm | 22 | $14,586 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $13,064 |
| Lacosamide | 60 | $11,907 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 376 | $6,959 |
| Clobazam | 13 | $6,297 |
| Levetiracetam | 219 | $6,069 |
| Felbamate | 13 | $4,760 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $4,208 |
| Zolmitriptan | 41 | $3,932 |
| Memantine Hcl | 175 | $2,730 |
| Carbamazepine | 42 | $2,498 |
| Entacapone | 24 | $2,259 |
| Donepezil Hcl | 398 | $2,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $471 | $93,65313 claims |
| PfizerNurtec Odt | $25 | $38,46627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 neurology providers in Nebraska.
Other neurology in Lincoln
- Gary PatteeLincoln$132K
- James BobenhouseLincoln$14K
- Ana DelgadoLincoln$11K
- Michael VavraLincoln$7K
- Matthew PurbaughLincoln$7K
- Matthew KnissLincoln$5K
- Daniel Crespo ArtunduagaLincoln$5K
- Vekash RajaLincoln$3K
- Erin DennisLincoln$2K
- Navya JosephLincoln$768
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.